YOLFTbeta
67

Alar Pharmaceuticals Inc.

6785 · TWO · Healthcare / Drug Manufacturers - Specialty & Generic

80.70TWD-0.20 (-0.25%)

Price History

Full chart

Market Stats

Previous Close80.90
Open80.10
Day Range80.00 – 84.00
52-Week Range90.60 – 316.68
Volume24.23K
Market Cap6.33B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.07
Dividend Yield0.11%
Beta0.12
50-Day Avg97.29
200-Day Avg162.98

About

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson's disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEODr. Yung-Shun Wen Ph.D.
  • Employees32
  • HeadquartersNo. 32, Keya Road, Taichung, Taiwan, Taiwan
  • Websitehttps://alarpharm.com

Leadership

  • Dr. Yung-Shun Wen Ph.D.CEO, Manager & Director
  • Ms. Vivian KangAccounting Supervisor & Director of Finance

Financials

Income Statement

Currency: TWD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue600.00K0800.00K469.27M5.82M2.75M
Growth (%)--100.00%-+58559.00%-98.76%-52.67%
Cost of Revenue---02.03M613.00K
Gross Profit600.00K-800.00K469.27M3.79M2.14M
Gross Margin100.00%-100.00%100.00%65.15%77.73%
Operating Expense143.36M-33.32M78.10M71.73M169.94M
Operating Income-142.76M-64.21M-32.52M391.17M-67.94M-167.80M
Operating Margin-23794.00%--4064.50%83.36%-1168.02%-6095.10%
EBITDA-139.92M-60.85M-29.31M394.52M40.96M-74.02M
EBITDA Margin-23320.17%--3663.75%84.07%704.09%-2688.85%
Net Income-142.80M-64.23M-19.87M382.62M18.17M-79.68M
Net Income Margin-23799.50%--2483.88%81.53%312.36%-2894.41%
R&D160.33M81.89M34.18M56.71M57.34M156.51M
R&D as % of Total Revenue26721.33%-4272.75%12.09%985.73%5685.11%
Interest Expense33.00K21.00K22.00K63.00K27.00K81.00K
Interest Expense % of Total Revenue5.50%-2.75%0.01%0.46%2.94%

Balance Sheet

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-603.98M539.91M522.60M973.21M2.56B2.49B
Total Liabilities145.00K5.37M5.54M8.10M76.09M64.26M84.34M
Total Equity-598.60M534.37M514.50M897.12M2.49B2.40B
Cash-560.96M519.07M455.35M739.46M1.41B1.79B
Total Debt-1.52M949.00K2.69M1.41M--
Net Debt--559.44M-518.12M-452.66M-738.05M--

Cash Flow

Currency: TWD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-141.92M-63.47M-32.95M403.57M-75.27M-171.03M
Financing Cash Flow549.11M-932.00K-929.00K-1.28M--
Capital Expenditure385.00K1.58M1.14M6.34M1.23M2.87M
Free Cash Flow-142.31M-65.05M-34.09M397.23M-76.50M-173.90M
Dividends Paid----100.20M16.70M
FCF to OCF100.27%102.48%103.46%98.43%101.64%101.68%
Dividend Paid to FCF-----130.98%-9.60%

Earnings

Report DateAug 7, 2024Nov 6, 2024
EPS Estimate0.00-0.19
EPS Actual-0.05-0.22
Surprise--15.79%
TimingAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap6.33B
Enterprise Value4.32B
Trailing P/E0.00
Forward P/E0.00
Price / Sales2108.65
Price / Book2.78
EPS-1.07
Book Value35.58
Revenue (TTM)3.00M
Gross Profit (TTM)2.59M
EBITDA-168.45M
Profit Margin0.00%
Operating Margin464.48%
Return on Equity-2.99%
Return on Assets-4.30%
Shares Outstanding66.80M
Shares Float40.29M
Beta0.12
Dividend Yield0.11%
Dividend Rate0.10
Payout Ratio0.00%

Dividends

20261×
0.10Aug 25, 2026
20251×
0.25Jun 10, 2025
20241×
1.50Jun 5, 2024